• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Averion Revenues Double Following Hesperion Acquisition

Averion Revenues Double Following Hesperion Acquisition

November 18, 2008
CenterWatch Staff

Averion, a contract research organization (CRO) specializing in oncology, reported its third quarter revenues more than doubled following its acquisition of Swiss CRO Hesperion.

Net service revenue for the three months ended September 30 was $15.9 million, compared with $7.8 million for the same period last year. The Southborough, Mass.-based company’s direct expenses for the third quarter of 2008 increased $5.7 million over third quarter 2007 to $9.9 million. The Hesperion acquisition, completed in October 2007, contributed $5.4 million to those third quarter expenses.

“We continued to realize positive trends in our net service revenue despite the difficulties facing many of our clients who are currently seeking additional sources of funds,” said Averion CEO Markus Weissbach, M.D., Ph.D., in a company statement. “We continue to manage our business very carefully and capitalize on the efficiencies of our expanded international operations through the integration of Hesperion and Averion.”

Averion expanded its European operations last month with the opening of a Czech Republic office, and the CRO continues to look for other expansion opportunities (both geographically and in the services it provides), according to Weissbach. Averion has U.S. offices in California, Maryland and New York; and international offices in France, the Netherlands, the United Kingdom, Poland, Russia, Israel, Germany, Austria, Ukraine and the Czech Republic.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing